Robin Norris, MD, MS, MPH

Systematic Review of Pain Assessment Measures Used in Pediatric Acute Lymphoblastic Leukemia. Klages, KL; Gibson, CA; Barnett, KA; Schwartz, LE; Hicks, CA; Norris, RE; Kashikar-Zuck, S; Pai, AL H. Psycho-Oncology: journal of the psychological, social and behavioral dimensions of cancer. 2025; 34:e70063.

Body Image Concerns in Adolescent and Young Adult Oncology Patients within Six Months of Upfront Diagnosis. D’Alessandro, PR; McGrady, ME; Nagata, JM; Norris, RE; Pressey, JG. Journal of Adolescent and Young Adult Oncology. 2024; 13:792-798.

Clinical outcomes of hypomethylating agents and venetoclax in newly diagnosed unfit and relapsed/refractory paediatric, adolescent and young adult acute myeloid leukaemia patients. LeBlanc, FR; Breese, EH; Burns, KC; Chang, EK; Jones, LQ M; Lee, L; Mizukawa, B; Norris, RE; O'Brien, MM; Phillips, CL; Perentesis, JP; Rubinstein, J; Pommert, L. British Journal of Haematology. 2024; 205:1055-1066.

Feasibility pilot trial of a tailored medication adherence-promotion intervention for adolescents and young adults with cancer: Study design and protocol. McGrady, ME; Ketterl, TG; Webster, RT; Schwartz, LE; Brock, MY; Szulczewski, L; Burke, M; Hommel, KA; Pai, AL H; Mara, CA; Steele, AC; Regan, GG; Norris, RE. Contemporary Clinical Trials. 2024; 139:107483.

Palbociclib in combination with chemotherapy in pediatric and young adult patients with relapsed/refractory acute lymphoblastic leukemia and lymphoma: A Children's Oncology Group study (AINV18P1). Raetz, EA; Teachey, DT; Minard, C; Liu, X; Norris, RE; Denic, KZ; Reid, J; Evensen, NA; Gore, L; Fox, E; Loh, ML; Weigel, BJ; Carroll, WL. Pediatric Blood and Cancer. 2023; 70:e30609.

Clinical trials: A plea to cooperative groups, consortia, pharmaceutical companies, and lead investigators for reasonable imaging protocols. Trout, AT; Norris, RE; de Blank, PM K; Backus, LR; Towbin, AJ; Nash, JM. Pediatric Blood and Cancer. 2023; 70:e30362.

Brentuximab vedotin after autologous transplantation in pediatric patients with relapsed/refractory Hodgkin lymphoma. Forlenza, CJ; Rosenzweig, J; Mauguen, A; Buhtoiarov, I; Cuglievan, B; Dave, H; Deyell, RJ; Flerlage, JE; Franklin, AK; Krajewski, J; Willen, F; Yan, AP; Harker-Murray, PD; Giulino-Roth, L. Blood Advances. 2023; 7:3225-3231.

The Choice of Either Conventional Chemotherapy or Inotuzumab Ozogamicin as Bridging Regimen Does Not Appear To Impact Clinical Response to CD19-Directed CAR-T Therapy in Pediatric B-ALL. Rubinstein, JD; Breese, EH; Krupski, MC; O'Brien, MM; Dandoy, CE; Mizukawa, B; Khoury, R; Norris, RE; Davies, SM; Phillips, CL. Transplantation and Cellular Therapy. 2023; 29:311.e1-311.e7.

Barriers to medication adherence among adolescents and young adults with cancer. McGrady, ME; Ketterl, TG; Norris, RE; Perentesis, JP; Pettee, D; Mara, CA; Breen, G; Pai, AL H. Pediatric Blood and Cancer. 2023; 70:e30186.

Ibrutinib plus RICE or RVICI for relapsed/refractory mature B-cell non-Hodgkin lymphoma in children and young adults: SPARKLE trial. Burke, GA A; Vinti, L; Kabickova, E; Beishuizen, A; Tacyildiz, N; Uyttebroeck, A; Kang, HJ; Luisi, F; Minard-Colin, V; Burkhardt, B; Srinivasan, S; Bhojwani, D; Norris, R; Cairo, M. Blood Advances. 2023; 7:602-610.